Real-world evaluation of pertuzumab and trastuzumab compared to trastuzumab chemotherapy backbone for first-line treatment of patients with HER-2 positive unresectable locally recurrent or metastatic breast cancer | UNB

Global Site Navigation (use tab and down arrow)

NB-IRDT

Real-world evaluation of pertuzumab and trastuzumab compared to trastuzumab chemotherapy backbone for first-line treatment of patients with HER-2 positive unresectable locally recurrent or metastatic breast cancer

Category(s): Health
Status: Active
Principal: Ted McDonald
Project Number: P0056
Year Approved: 2020

Project Description

It is widely known that drug funding decisions and clinical practice are informed by predictive economic modelling based on clinical trials data. However the benefits observed in the highly structured clinical trials are not necessarily reflective of real-world effects. A pan-Canadian initiative called the CanREValue collaboration has been created to develop a framework to include real-world evidence in cancer drug funding decisions using consistently defined real-world data from across Canadian provinces. As part of the CanREValue collaboration, this project will examine the real-world overall effectiveness, safety, and budget impact of a novel cancer drug compared to the previous standard of care for patients with HER-2 positive advanced stage breast cancer.

Read the report: